Omada Health

NASDAQ:OMDA

Medical - Healthcare Information Services

Healthcare
$13.17 +0.78%

+$0.13 today

Market cap
$817.04M
Beta
2.09
P/E (TTM)
-162.6
EPS (TTM)
-$0.11
52W Low $10.28High $26.92

Volume 1.68M

Average 1.07M

OMDA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Omada HealthNASDAQ: OMDA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $739K fell 91.6% year over year, behind the -8.9% change in trailing-twelve-month research & development. Sequentially, it fell 93.6% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Research & development amounted to 15.6% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -91.6% toward the trailing-twelve-month pace of -8.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$739K-93.6% QoQ
Last fiscal yearDec 2025
$40.68M+13.3% YoY
LTMMar 2026
$32.6M-8.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.6%——
1 year+13.3%——
3-year CAGR+15.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
40.68M USD
Year-over-year change
+13.3%
3-year CAGR
+15.8%

Research & Development vs competitors

How OMDA compares with its peers on the latest reported figures

  • OMDA's LTM Mar 2026 research & development of $32.6M is the lowest of the 5 companies compared; the peer median is $143.18M.
  • Its year-over-year change of -8.9% is the 3rd highest of 5, against a peer median of -9.0%.
  • Research & development amounts to 11.5% of revenue for OMDA, versus a peer median of 15.3%.
OMDA Competitors Peer median
Research & Development for OMDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$320.12M +4.5%-5.9%12.7%
HIMSHims & Hers Health, Inc.LTM Sep 2026$157.29M +19.1%+72.2%5.5%
HNGEHinge Health, Inc.LTM Jun 2026$129.07M -63.1%—17.9%
AMWLAmerican Well CorporationLTM Mar 2026$63.14M -22.5%-19.3%26.6%
OMDAOmada HealthLTM Mar 2026$32.6M -8.9%+15.8%11.5%
Peer median (excluding OMDA) $143.18M-9.0%-5.9%15.3%

Competitors are the stored peer set for OMDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue89.19M122.78M169.8M260.21M
Cost of Revenue46.39M52.81M66.92M89.27M
Gross Profit42.79M69.97M102.88M170.94M
Gross Margin48.0%57.0%60.6%65.7%
Research & Development26.17M33.74M35.92M40.68M
Selling, General & Admin88.97M102.23M110.61M142.23M
Operating Expenses115.14M135.97M146.53M182.91M
Depreciation & Amortization4.33M4.45M4.8M5.49M
EBITDA(63.99M)(58.36M)(37.83M)(4.75M)
EBITDA Margin-71.7%-47.5%-22.3%-1.8%
Operating Income(72.35M)(66M)(43.65M)(11.97M)
Operating Margin-81.1%-53.8%-25.7%-4.6%
Interest Income2.2M5.78M805K5.31M
Interest Expense4.2M4.71M4.51M2.53M
Other Income / Expenses(168K)(1.51M)(3.48M)(806K)
Income Before Tax(72.52M)(67.51M)(47.14M)(12.78M)
Pre-Tax Margin-81.3%-55.0%-27.8%-4.9%
Income Tax Expense0000
Net Income(72.52M)(67.51M)(47.14M)(12.78M)
Net Margin-81.3%-55.0%-27.8%-4.9%
EPS (Basic)(1.30)(1.21)(0.85)(0.22)
EPS (Diluted)(1.30)(1.21)(0.85)(0.22)
Weighted Avg Shares55.74M55.74M55.74M58.43M
Weighted Avg Shares (Diluted)55.74M55.74M55.74M58.43M

Omada Health

NASDAQ:OMDA

Intrinsic Alpha fair value

Locked

Current Price

$13.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.